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BACKGROUND: From March to April 2020, Spain was the center of the SARS-CoV-2
pandemic, particularly Madrid with approximately 30% of the cases in Spain. The aim of this
study is to report the suspected serious adverse drug reactions (SADRs) in COVID-19 patients
vs. non-COVID-19 patients detected by the prospective pharmacovigilance program based
on automatic laboratory signals (ALSs) in the hospital (PPLSH) during that period. We also
compared the results with the suspected SADRs detected during the same period for 2019.
METHODS: All ALSs that reflected potential SADRs including neutropenia, pancytopenia,
thrombocytopenia, anemia, eosinophilia, leukocytes in cerebrospinal fluid, hepatitis,
pancreatitis, acute kidney injury, rhabdomyolysis, and hyponatremia were prospectively
monitored in hospitalized patients during the study periods. We analyzed the incidence
and the distribution of causative drugs for the COVID-19 patients.
RESULTS: The incidence rate of SADRs detected in the COVID-19 patients was 760.63
(95%CI 707.89–816.01) per 10,000 patients, 4.75-fold higher than the SADR rate for non-
COVID-19 patients (160.15 per 10,000 patients, 95% CI 137.09–186.80), and 5.84-fold
higher than the SADR rate detected for the same period in 2019 (130.19 per 10,000
patients, 95% CI 109.53–154.36). The most frequently related drugs were tocilizumab
(59.84%), dexketoprofen (13.93%), azithromycin (8.43%), lopinavir-ritonavir (7.35%),
dexamethasone (7.62%), and chloroquine/hydroxychloroquine (6.91%).
CONCLUSIONS: The incidence rate of SADRs detected by the PPSLH in patients with
COVID-19 was 4.75-fold higher than that of the non-COVID-19 patients. Caution is
recommended when using medications for COVID-19 patients, especially drugs that
are hepatotoxic, myotoxic, and those that induce thromboembolic events.
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INTRODUCTION
From March to April 2020, Spain was the center of the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
pandemic, (Center for Coordination of Health Alerts and
Emergencies) with Madrid accounting for approximately 30%
of the cases in Spain. (Current situation in the Community of
Madrid) In response, the Spanish Ministry of Health published
protocols for the care and management of COVID-19 patients.
Azithromycin, chloroquine, hydroxychloroquine and lopinavir/
ritonavir have been recommended for treatment during the
infectious phase. Subsequently, anti-inflammatory drugs (such
as corticosteroids and other compounds) were recommended
for COVID-19 patients who progressed to the inflammatory
phase of the disease. The drugs employed during that period
were off-label or under development as potential treatment
options for COVID-19.
In this situation, more attention should be paid to the safety
of these drugs, whose toxicity profile is relatively well
understood based on trials and the post-marketing
experience in the indications for which they are approved.
(Spanish Agency for Medicines and Health Products; Spanish
Agency for Medicines and Health Products; Spanish Agency for
Medicines and Health Products; Spanish Agency for Medicines
and Health Products; Spanish Agency for Medicines and Health
Products; Spanish Agency for Medicines and Health Products)
Although the most frequent reactions to these drugs are usually
mild, serious adverse effects have also been reported with their
use. It is also unclear whether the use of these drugs by COVID-
19 patients poses greater risks, because COVID-19 itself could
be a predisposing factor to certain serious adverse drug
reactions (SADRs).
In recent decades, large, computerized clinical databases
linked to electronic medical records (EMRs) have helped
implement prospective programs for detecting SADRs and
aiding clinicians in reacting quickly and appropriately to
these reactions. (Hannan, 1999) Since 2007, our hospital
has employed a prospective pharmacovigilance program
based on the systematic detection of predefined abnormal
laboratory signals (ALSs) through our laboratory
information system (Pharmacovigilance Program from
Laboratory Signals in Hospital [PPLSH]) for the early
detection of SADRs. The screening for specific anomalous
laboratory data enables us to monitor a large number of
patients with limited resources, thereby accessing high-
quality information in a timely manner. (Ramirez et al.,
2010) We conducted a thorough evaluation of ALSs during
the current pandemic to help detect those events associated
with the treatments and the disease and provide a basis for
decision making in drug risk management during a possible
second wave of the pandemic.
The aim of the study was to report the suspected SADRs in
COVID-19 patients vs. non-COVID-19 patients detected by the
PPLSH from March to April 2020. We also compared the results




La Paz University Hospital in Madrid, Spain, is a tertiary-care
teaching facility, where all admissions to wards are monitored
by the PPLSH. The program was conducted according to the
Spanish Personal Data Protection Law, (Organic law 3/2018,
december 5, 2018, protection of personal data and guarantee of
digital rights (BOE núm. 294, 119788-11985) and approval for
publishing the program was obtained from the Institutional
Review Board at La Paz University Hospital (protocol PI-
3226). The technical document of the Spanish Ministry of
Health for the clinical management of COVID-19 in
emergencies and in hospital was adapted and implemented
in the hospital. (Spanish Ministry of Health; World Health
Organization).
Information System and Coverage
A specific database application was developed within the
integrated laboratory system (Labtrack Integrated Laboratory
System), available in the hospital since 2003, which we
employed to collect the predefined ALSs. We reviewed all
ALSs retrieved systematically from these patients’ medical
records.
At the time of the study, all of the patients’ medical
information was collected in the hospital’s EMRs and included
all laboratory data, imaging and other exploratory results,
previous medical reports, medication prescription record,
comments on the patients’ progression, and discharge
summaries. Discharge summaries were coded according to
International Statistical Classification of Diseases and Related
Health Problems tenth revision (ICD-10).
Hospital laboratories that conduct blood tests for inpatients
and emergency patients are certified and accredited under the
appropriate International Standards Organization (ISO 9001:
2000 and ISO 15189).
Definition of Signals
Table 1 lists the criteria for selecting the drug-induced ALS.
Definitions of Adverse Drug Reaction
We employed the E2D definition of SADR of the International
Council for Harmonisation of Technical Requirements for
Pharmaceuticals for Human Use. (ICH Guideline on E2D
Postapproval Safety Data Management: Definitions and
Standards for Expedited Reporting) For the program’s
purposes, we excluded ADRs caused by accidental or
intentional overdose, as well as medical errors, which we
considered to be any error in the written prescription,
dispensation or administration. Errors in decision making (use
in contraindicated clinical conditions or drug interactions) were
considered SADRs and were therefore included. Adverse
reactions caused by chemotherapy drugs were excluded from
hematological ALSs, given that agranulocytosis, anemia,
pancytopenia and thrombocytopenia are expected and
explained by the pharmacodynamic properties of these drugs.
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Detecting and Evaluating Adverse Drug
Reactions
The procedure for detecting and evaluating ADRs has been
described elsewhere. (Yelehe-Okouma et al., 2018) Briefly, in
phase I, on-file laboratory data at admission or during
hospitalization were screened 7 days a week, 24 h a day, for
ALS fromMarch to April 2019 and for the same period in 2020.
In phase II, the patients were identified to avoid duplicates, and
EMRs were reviewed. In phase III, a case-by-case evaluation
was performed for the remaining cases (Figure 1). The
causality assessment was performed using the algorithm of
the Spanish Pharmacovigilance System. (Aguirre and García,
2016) We considered the categories of possible, probable or
definite for drug-related reactions. Regarding the evaluation of
the drug cause vs. the alternative cause (nondrug-induced), we
only considered a drug cause when there was no alternative
cause to explain the signal and, for the COVID-19 patients,
when there was a dissociation between the clinical and lab
parameters for improvement but a worsening of the ALS in the
evaluation.
Monitoring COVID-19 Patients
During hospitalization, patients with COVID-19 infection were
monitored by their physicians to assess hepatic and renal function
(alanine aminotransferase), aspartate aminotransferase, alkaline
phosphatase, creatinine, gamma-glutamyl transferase, glomerular
filtration rate, bilirubin, prothrombin activity and
thromboembolic risk (hemoglobin, Chronic Kidney Disease
Epidemiology Collaboration equation, D-dimer, fibrinogen,
platelets). The lab controls varied depending on the patients’
clinical situation, usually daily during the first three weeks. We
evaluated the laboratory test results for each drug for treating
COVID-19 using the following structure: The baseline value was
the value before drug administration; value 1 was the first value
after administration; values 2–19 were the values on days 1–20
after the first dose administration; and values 20–39 were the
results between days 21 and 60 after dose administration during
the hospitalization.
Collection of Patient Data and Reporting
For all patients initially categorized as having a suspected SADR, a
complete report was submitted to the pharmacovigilance center
in Madrid (https://www.notificaram.es).
Data Analysis
The results are presented using central tendency measures
(mean for quantitative variables and median for ordinal
ones) and measures of dispersion (standard deviation and
interquartile range, respectively) and percentages (95%
confidence interval) for discrete variables. The in-hospital
incidence rate for each SADR and other etiologies of ALS
were calculated by dividing the number of cases of drug-
induced reactions in hospitalized or deceased patients in the
emergency department by the number of patients hospitalized
during the selected months. We assessed the uncertainty of
association by calculating the 95% two-sided Poisson confidence
interval. The chi-squared test was performed to compare sex
distribution and morbidity variables, and Student’s t-test or the
Mann Whitney test, as appropriate, was used to compare the
ages of patients in the SADR cohorts. We employed IBM SPSS
Statistics for Windows, Version 20.0 (IBM Corporation,
Armonk, NY, US) for the statistical analysis.
RESULTS
A total of 7,365 patients were hospitalized from March 1 to April
30, 2020, 2,682 (36.4%) of whom had COVID-19 infection.
Figure 2 shows the sequence of drugs administered in the
various phases of COVID-19 disease. The number of cases
with ALS during the period was 1,341, with 575 COVID-19
patients and 766 non-COVID-19 patients. The COVID-19
patients had fewer hematological, pancreatitis and
hyponatremia ALSs but more hepatitis, acute kidney injury,
and rhabdomyolysis ALSs (Table 2). There were 1,153 cases
with ALSs in the same period for 2019. The patients with
COVID-19 in 2020 had an overall 3-fold higher rate of
suspected SADRs than the non-COVID-19 patients in 2020
and 2019 (35.5% vs. 9.8% and 9.2%, respectively), with the
following rates of SADRs: pancytopenia (57.1% vs. 1.4% and
4.5%), agranulocytosis (50% vs. 2.8% and 14.7%),
thrombocytopenia (100% vs. 6.3% and 5.9%), anemia (43.8%
vs. 3.2% and 27.6%), eosinophilia (14.1% vs. 5.7% and 4.1%),
leukocytes in the cerebrospinal fluid (50% vs. 20.8% and 5.4%),
hepatitis (45.1% vs. 23.7% and 12.4%), pancreatitis (58.3% vs.
15.6% and 7%), acute kidney injury (21.4% vs. 1.0% and 8.8%),
rhabdomyolysis (15.3% vs. 4.4% and 9.5%) and hyponatremia
(94.4% vs. 25.0% and 27.8%) (Table 2). The incidence rate of
TABLE 1 | Definition of automatic laboratory signals used to detect serious
adverse drug reactions.
Agranulocytosis
Neutrophils <0.5 × 103/µl, hemoglobin ≥10 g/dl, platelets ≥ 100 × 103/µl
Pancytopenia
White blood cells ≤ 3.5 × 103/µl, hemoglobin ≤10 g/dl, platelets ≤ 50 × 103/µl
Thrombocytopenia




Eosinophils >0.8 × 103/with organ involvement or systemic symptoms
Leukocytosis in the cerebrospinal fluid
Leukocytes ≥ 10 mm3
Liver injury
ALAT x 5 ULN IU/L
Pancreatitis
Amylase x 3 ULN IU/L or lipase x 3 ULN
Acute kidney injury




Creatine kinase x 5 ULN IU/L
ALAT, alanine aminotransferase; ULN, upper limit of normal.
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suspected SADRs detected by PPLSH in the COVID-19 patients
was 760.63 (95% CI 707.89–816.01) per 10,000 patients, 4.75-fold
higher than the SADR rate in the non-COVID-19 patients for the
same period (160.15 per 10,000 patients, 95% CI 137.09–186.80)
and 5.84-fold higher than the SADR rate for the same period in
2019 (130.19, 95% CI 109.53–154.36) (Table 3). The description
of the demographic characteristics and morbidities of the patients
who had SADRs during the study periods are shown in Table 4.
Non-COVID-19 patients with SADRs were significantly older
and there were significantly more females that COVID-19
patients, but the morbidities did not show significant
differences between cohorts. Table 5 lists the drugs that most
frequently produced SADRs in the COVID-19 patients, which
includes: tocilizumab (59.84%), dexketoprofen (13.93%),
azithromycin (8.43%), lopinavir-ritonavir (7.35%),
dexamethasone (7.62%), and chloroquine/hydroxychloroquine
(6.91%). The overall mortality rate for the COVID-19 vs. the
non-COVID-19 patients (in 2020 and 2019) was 21.6% vs. 3.6%
and 3.0%, respectively. The mortality rate for the COVID-19
patients with SADRs vs. the non-COVID-19 patients with SADRs
(in 2020 and 2019) was 30.5% vs. 3.9% and 3.3%, respectively.
Table 5 lists the mortality rate per drug for COVID-19 patients
with SADRs.
At the time of hospitalization, the COVID-19 patients had
slightly abnormal liver function, based on alanine
aminotransferase and gamma-glutamyl transferase levels that
were slightly above the upper limit of normality (ULN), which
were normal in most patients. Figure 3 shows the statistically
significant worsening of liver function in the COVID-19 patients
associated with the drugs used in phase I of the infection. Liver
FIGURE 1 |Methodology of the Pharmacovigilance Program From Laboratory Signals in Hospital. Abbreviations: ALS, automatic laboratory signal; EMR, electronic
medical record; SADR, serious adverse reaction.
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function parameters in the patients who took ceftriaxone typically
increased by the end of the first week, in patients who took
azithromycin increased in the second week, and in the patients
who took lopinavir-ritonavir or hydroxychloroquine
increased in the third week. However, liver function
trended towards normalization during hospitalization for
the patients who took dexamethasone. Metamizole and
paracetamol showed no statistically significant effect. At the
time of hospitalization, the COVID-19 patients had an
increased thromboembolic risk measured by the number of
fold increases in D-dimer levels above the ULN. Figure 4
shows the worsening of D-dimer, fibrinogen, and hemoglobin
levels in the patients treated with the various drugs during
phase II of the infection. Tocilizumab and dexamethasone
produced a statistically significant reduction in fibrinogen and
hemoglobin levels, along with a significant increase in
D-dimer levels. Oral anticoagulants, dexamethasone and
low-molecular-weight heparins were associated with a
decrease in hemoglobin levels after the start of the drug in
this hospitalization phase.
DISCUSSION
Since 2007, physicians of the Clinical PharmacologyDepartment of
our hospital maintain uninterruptedly a pharmacovigilance
program based on laboratory signals using its available
information systems. ALSs were chosen on the basis that they
were detectable in the routine tests of almost all laboratories and
were therefore easily detectable in inpatients and because the ALSs
could warn of relevant SADRs with significant impact on patient
health and wellbeing. Agranulocytosis, aplastic anemia,
eosinophilia, liver injury, and rhabdomyolysis are frequently
evaluated ALSs in the literature. (Risks of agranulocytosis and
aplastic anemia. A first report of their relation to drug use with
special reference to analgesics. The International Agranulocytosis
and Aplastic Anemia Study, 1986; Ramírez et al., 2017; Andrade
et al., 2005; Wen et al., 2019) Thrombocytopenia, anemia,
leukocytes in cerebrospinal fluid, pancreatitis, acute kidney
injury, and hyponatremia are increasingly frequent drug-
induced reactions. (Aster and Bougie, 2007; Carnovale et al.,
2015; Yelehe-Okouma et al., 2018; Wu and Huang, 2018;
Ramírez et al., 2019; Zheng et al., 2019) This study enabled us
to detect a relevant number of ALSs that are potentially related to
SADRs and to determine their in-hospital incidence. During
March-April 2020, there was a significant 72% reduction in the
number of spontaneous SADRs (not from the PPLSH) compared
with the same period in 2019, although 4 drug reactions with
eosinophilia and systemic symptoms, 2 cases of Stevens Johnson
syndrome, and 1 case of acute generalized exanthematous
pustulosis were included. In addition, we considered a
spontaneous SADR as a sentinel event that motivated a root
cause analysis from the hospital, which included, as an
improvement action, a drug safety note for the Spanish Agency
for Medicine and Health Products.
Overall, we detected a 5.8-fold higher rate of SADRs in the
COVID-19 patients than during the same period of the previous
year. The use of off-label medicines has been associated with more
ADRs than the use of labeled medicines. (Bellis et al., 2014; Viola
et al., 2016; Auffret et al., 2017), This off-label use would be
acceptable if the evidence of potential benefits outweighs the
ADR risk. More than 150 clinical trials are currently underway
to study drugs that prevent or treat COVID-19 infection, some of
which have shown no benefit, such as lopinavir-ritonavir,
azithromycin, chloroquine and hydroxychloroquine. (Cao et al.,
2020; Rosenberg et al., 2020; Tang et al., 2020a) During the COVID-
FIGURE 2 | COVID-19 infection stages and treatments employed. Abbreviations: LMWH, low-molecular-weight heparin; Ig, immunoglobulin; IV Ig, intravenous
immunoglobulin; IF β-1b, interferon beta-1b; SADRs, serious adverse drug reactions.
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19 pandemic period, we detected more SADRs in the non-COVID-
19 patients than during the same period in 2019, an effect that can
be explained by the overloading of the health system, which resulted
in a patient safety problem: changes in prescription due to supply
problems, insufficient deprescribing, more empiric treatments, and
drug interactions in non-COVID-19 patients.
TABLE 2 | Breakdown by no SADR group vs. SADR group recorded from March
to April 2020 in COVID-19 patients vs. non-COVID-19 patients.
Date March to April 2020
Cohort COVID-19 patients
Signal category No SADR SADR Total Signals
n % n % n %
Pancytopeniaa 3 42.9 4 57.1 7 8.9
Agranulocytosisa 6 50.0 6 50.0 12 25.0
Thrombocytopeniaa 0 0.0 2 100.0 2 11.1
Anemiaa 9 56.3 7 43.8 16 20.5
Eosinophilia 67 85.9 11 14.1 78 30.8
Leukocytes CSF 1 50.0 1 50.0 2 7.7
Hepatitis 141 54.9 116 45.1 257 62.2
Pancreatitis 5 41.7 7 58.3 12 21.1
AKI III 88 78.6 24 21.4 112 52.1
Rhabdomyolysis 50 84.7 9 15.3 59 56.7
Hyponatremia 1 5.6 17 94.4 18 36.0
TOTAL 371 64.5 204 35.5 575 42.9
Date March to April 2020
Cohort Non-COVID-19 patients
Signal category No SADR SADR Total Signals
n % n % n %
Pancytopeniaa 71 98.6 1 1.4 72 91.1
Agranulocytosisa 35 97.2 1 2.8 36 75.0
Thrombocytopeniaa 15 93.8 1 6.3 16 88.9
Anemiaa 60 96.8 2 3.2 62 79.5
Eosinophilia 165 94.3 10 5.7 175 69.2
Leukocytes CSF 19 79.2 5 20.8 24 92.3
Hepatitis 119 76.3 37 23.7 156 37.8
Pancreatitis 38 84.4 7 15.6 45 78.9
AKI III 102 99.0 1 1.0 103 47.9
Rhabdomyolysis 43 95.6 2 4.4 45 43.3
Hyponatremia 24 75.0 8 25.0 32 64.0
TOTAL 691 90.2 75 9.8 766 57.1
Date March to April 2019
Cohort All ALS patients
Signal category No SADR SADR Total Signals
n % n % n %
Pancytopeniaa 84 95.5 4 4.5 88 7.6
Agranulocytosisa 29 85.3 5 14.7 34 2.9
Thrombocytopeniaa 16 94.1 1 5.9 17 1.5
Anemiaa 42 72.4 16 27.6 58 5.0
Eosinophilia 347 95.9 15 4.1 362 31.4
Leukocytes CSF 35 94.6 2 5.4 37 3.2
Hepatitis 184 87.6 26 12.4 210 18.2
Pancreatitis 53 93.0 4 7.0 57 4.9
AKI III 155 91.2 15 8.8 170 14.7
Rhabdomyolysis 76 90.5 8 9.5 84 7.3
Hyponatremia 26 72.2 10 27.8 36 3.1
TOTAL 1,047 90.8 106 9.2 1,153 100.0
Breakdown by no SADR group vs. SADR group recorded fromMarch to April 2019. AKI,
acute kidney injury; ALS, automatic laboratory signals; CSF, cerebrospinal fluid; IR,
incidence rate per 10,000 patients; SADR, serious adverse drug reaction.
aSADRs by antineoplastic agents are in the no ADR group.
TABLE 3 | Incidence rate (Poisson 95% CI) per 10,000 patients of no SADR vs.
SADR recorded from March to April 2020 in COVID-19 patients vs. non-
COVID-19 patients.
Date March to April 2020
COVID-19 cohort COVID-19 patients
Signal category No SADR SADR
IR 95% CI IR 95% CI
Pancytopeniaa 11.19 6.20 19.68 14.91 8.40 23.50
Agranulocytosisa 22.37 14.58 33.31 22.37 14.58 33.31
Thrombocytopeniaa 0.00 0.0 3.7 7.46 3.45 14.42
Anemiaa 33.56 23.55 46.34 26.10 17.80 38.10
Eosinophilia 249.81 219.97 281.93 41.01 30.27 55.62
Leukocytes CSF 3.73 1.09 8.77 3.73 1.09 8.77
Hepatitis 525.73 482.00 571.89 432.51 393.17 474.72
Pancreatitis 18.64 11.44 28.45 26.10 17.79 38.10
AKI III 328.11 294.41 365.49 89.49 72.37 109.52
Rhabdomyolysis 186.43 161.16 214.74 33.56 23.55 46.34
Hyponatremia 3.73 1.09 8.77 63.39 49.29 80.60
TOTAL 1,383.30 1,312.04 1,457.86 760.63 707.89 816.01
Date March to April 2020
COVID-19 cohort Non-COVID-19 patients
Signal category No SADR SADR
IR 95% CI IR 95% CI
Pancytopeniaa 151.61 128.80 177.10 2.14 0.62 7.22
Agranulocytosisa 74.74 58.99 92.90 2.14 0.62 7.22
Thrombocytopeniaa 32.03 22.72 45.17 2.14 0.62 7.22
Anemiaa 128.12 107.70 152.19 4.27 1.62 10.24
Eosinophilia 352.34 317.13 390.76 21.35 13.79 32.11
Leukocytes CSF 40.57 29.42 54.47 10.68 5.50 18.40
Hepatitis 254.11 224.66 287.23 79.01 62.44 98.46
Pancreatitis 81.14 65.22 100.68 14.95 8.40 23.49
AKI III 217.81 190.02 247.87 2.14 0.62 7.22
Rhabdomyolysis 91.82 74.17 111.73 4.27 1.63 10.24
Hyponatremia 51.25 38.83 67.06 17.08 10.67 27.22
TOTAL 1,475.55 1,401.65 1,552.24 160.15 137.09 186.80
Date March to April 2019
COVID-19 cohort All ALS patients
Signal category No SADR SADR
IR 95% CI IR 95% CI
Pancytopeniaa 328.31 294.41 365.49 4.91 1.63 10.24
Agranulocytosisa 164.16 140.78 191.11 6.14 2.81 13.06
Thrombocytopeniaa 72.96 57.22 90.67 1.23 0.24 5.57
Anemiaa 282.71 251.0 316.91 19.65 12.22 29.67
Eosinophilia 797.98 743.59 854.31 18.42 11.44 28.45
Leukocytes CSF 109.44 90.41 131.49 2.46 0.62 7.22
Hepatitis 711.34 660.66 765.24 31.93 21.89 44.00
Pancreatitis 205.19 178.83 235.07 4.91 1.63 10.24
AKI III 469.67 428.46 513.43 18.42 11.44 28.45
Rhabdomyolysis 205.19 178.83 235.07 9.83 4.80 17.08
Hyponatremia 145.92 123.28 170.62 12.28 6.92 20.96
TOTAL 3,492.85 3,378.11 3,609.78 130.19 109.53 154.36
Incidence rate of no ADR vs. ADR recorded from March to April in 2019. AKI, acute
kidney injury; ALS, automatic laboratory signals; CSF, cerebrospinal fluid; IR, incidence
rate per 10,000 patients; SADR, serious adverse drug reaction.
aSADRs by antineoplastic agents are in the no ADR group.
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The PPLSH detected that 35.5% of the ALSs in the COVID-19
patients were SADRs, which agrees with the results from the China
Hospital Pharmacovigilance System that detected ADRs in 37.8% of
COVID-19 patients, which were predominately drug-induced
gastrointestinal disorders and liver disorders (23.0% vs. 13.8%
respectively). (Sun et al., 2020) Drug-induced liver injury was
the most frequent SADR detected (116/204, 56.86%) in the
study. Liver damage in mild cases of COVID-19 is often
transient, and liver function can return to normal without
special treatment. (Alqahtani and Schattenberg, 2020) Moderate
and severe liver damage could be drug-induced, which might
explain the large variation in liver impairment observed across
the various cohorts. (Aggarwal et al., 2020; Borobia et al., 2020;
Chen et al., 2020; Guan et al., 2020; Zhou et al., 2020) Immune-
mediated inflammation, such as cytokine storms and pneumonia-
associated hypoxia, might also have contributed to liver injury and
even to the development of liver failure in critically ill patients with
COVID-19. Figure 2 shows the increase in bilirubin and
transaminase levels in the patients hospitalized for more than 4
weeks, corresponding to the critically ill patients.
Increased D-dimer levels have been reported as one of the most
common laboratory findings in COVID-19 patients requiring
hospitalization. (Tang et al., 2020b) D-dimer levels on admission
4-fold higher than the ULN have been associated with in-hospital
mortality for patients with COVID-19. (Zhang et al., 2020) Despite
the difficulties in standardizing D-dimer levels, test kit
manufacturers, normal values and units, D-dimer is a marker of
thromboembolic disease and disseminated intravascular
coagulation. (Favaloro and Thachil, 2020) Drugs for treating
phase II of infection-associated hyperinflammatory syndrome
that can cause life-threatening acute respiratory distress
syndrome in patients with COVID-19 pneumonia can also cause
thromboembolic disease. These drugs include dexamethasone,
baricitinib, sarilumab, interferon beta 1B, and intravenous
immunoglobulins. (Spanish Agency for Medicines and Health
Products; Spanish Agency for Medicines and Health Products;
Spanish Agency for Medicines and Health Products; Spanish
Agency for Medicines and Health Products) Thrombocytopenia
has been associated with anakinra, and hypofibrinogenemia has
been related to tocilizumab. (Spanish Agency for Medicines and
Health Products; Spanish Agency for Medicines and Health
Products) Our study therefore reports a statistically significant
effect of hypofibrinogenemia with an increase in D-dimer levels
associated with tocilizumab and to a lesser extent with
dexamethasone. Anemization was also observed in the patients
treated with low-molecular-weight heparins or oral anticoagulants
during this phase of COVID-19.
This study’s main limitation is that the evaluation of causality of
a possible SADR does not completely exclude the influence of
COVID-19. Considering the current evidence, some overlap with
COVID-19 cannot be ruled out. However, a drug-related cause was
only considered when there was a dissociation between clinical
improvement and worsening of the ALS. Longer follow-up periods
are needed to assess the recovery or sequelae of these SADRs and to
study the immunological and pharmacogenetic mechanisms and
the re-exposure effects of these SADRs.
In conclusion, PPLSH has been useful in detecting and
evaluating specific SADRs during the avalanche of
hospitalizations of patients with COVID-19. The incidence rate
of SADRs detected by PPSLH in the patients with COVID-19 was
4.75-fold higher than that of the non-COVID-19 patients. Caution
is recommended in using drugs to treat patients with COVID-19,











Number, median age, years (range)
Adultsc 201, 69.8 (21–96) 63, 74 (20–95) <0.037 93, 75 (26–101) <0.001
Children 3, 11 (9–14) 12, 7 (1–16) — 13, 5.5 (0.1–16) —
Sex, n (%, 95% CI)
Male 151 (74, 66.4–81.6) 30 (40, 30.9–49.8) <0.001 46 (43.4, 33.7–52.8) <0.001
Female 53 (26, 18.4–35.4) 45 (60, 50.2–69.1) — 60 (56.6, 46.2–65.3) —
Comorbidities, n (%, 95% CI)
Arterial hypertension 83 (40.7, 30.9–49.8) 30 (40.0, 30.9–49.8) 1.000 42 (39.6, 30–48.8) 0.880
Chronic heart disease 15 (7.5, 3-4–13.7) 11 (14.3, 8.5–22.1) 0.110 16 (15.1, 9.3–23.3) 0.071
Diabetes mellitus 36 (17.6, 10-9–25.5) 16 (21.3, 14.2–30) 0.470 23 (21.7, 14.2–30) 0.470
Rheumatological disease 3 (1.5, 0.2–5.4) 2 (2.0, 0.6–7) 0.560 2 (1.5, 0.2–5.4) 1.000
Solid malignant disease 11 (5.4, 2.2–11.2) 5 (6.1, 2.8–12.5) 0.760 7 (6.6, 2.8–12.5) 0.760
Obesity 13 (6.3, 2.8–12.5) 6 (8.2, 4.1–15) 0.580 8 (7.5, 3.4–13.7) 0.770
Chronic kidney disease 14 (6.9, 2.8–12.5) 9 (12.0, 7–19.8) 0.140 13 (12.1, 7–19.8) 0.140
Chronic obstructive pulmonary disease 22 (10.8, 5.5–17.4) 12 (16.0, 10.1–24.4) 0.210 17 (16.0, 10.1–24.4) 0.210
Other chronic lung disease 13 (6.3, 2.8–12.5) 5 (6.1, 2.8–12.5) 1.000 8 (7.5, 3.4–13.7) 0.770
Hematological malignant disease 4 (2.0, 0.6–7) 3 (4.1, 1.6–9.8) 0.410 5 (4.7, 1.6–9.8) 0.410
Asthma 9 (4.4, 1.6–9.8) 3 (4.0, 1.6–9.8) 1.000 5 (4.5, 1.6–9.8) 1.000
Liver disease 12 (5.9, 2.2–11.2) 8 (9.3, 4.8–16.2) 0.270 10 (8.5, 4.1–15) 0.390
HIV Infection 1 (0.6, −0 to 3.7) 1.3 (2.0, 0.6–7) 0.160 2 (1.5, 0.6–5.4) 0.320
CI, confidence level.
aCOVID-19 patients vs. Non-COVID-19 patients 2020.
bCOVID-19 patients vs. Patients 2019.
c≥18 years old.
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Median (IQ) Median (IQ) Signal (n)
Azithromycin 1,008 66.8 (15.8) 57.6 4.3 6.5 1.8 6.4 1. 70.0 3 (1–12) 500 (400–600) Total (85), AA (1) E (2) H (74)





1924 67.3 (17.7) 56.8 3.9 7.2 6.0 5.4 1. 68.7 4.37 (1–36) 151 (100–800) Total (133), AA (3) A (3) T (1) E (7)
MEN (1) H (107) PC (2) R (1) NA (6) Tp (2)2. 24.0
3. 7.1
4. 0.2






































AA, aplastic anemia; A, agranulocytosis; AKI, acute kidney injury; AN, anemia; E, eosinophilia with organ involvement or systemic symptoms; Fib, hypofibrinogenemia; H, hepatitis; IQ, interquartile; LMWH, lowmolecular weight heparin; MEN,














































because the drugs cause additional damage, especially those that are
hepatotoxic, myotoxic, or induce thromboembolic events.
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FIGURE 3 | Sequence chart: Progression of parameters related to liver function in COVID-19 patients during hospitalization according to the treatment undergone.
The X-axis indicates the value number (baseline, the last value before drug administration; value 1, first value after administration; values 2–19, values on days 1–20 after
the first dose administration; values 20–39, results between days 21 and 60 of hospitalization). The Y-axis indicates the number of times above or below the limit of
normality, as appropriate. The red circle indicates the points with statistical significance. ALL, all patients; AZ, azithromycin; BLN, below limit of normal; CEF,
ceftriaxone; HQ, hydroxychloroquine; DEX, dexamethasone, L/r, lopinavir/ritonavir; MET, metamizole; PARA, paracetamol; ULN, upper limit of normality.
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